+32.0%
CTVA vs MRNA
+945.0%
-913.0%
-21.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.2% | +13.1% | -9.9% | +3.1% |
| 7D | +8.2% | +20.6% | -12.4% | +8.1% |
| 30D | -1.0% | +27.1% | -28.2% | -1.3% |
| 3M | +4.6% | +353.4% | -348.8% | +1.2% |
| 6M | +0.5% | +446.3% | -445.8% | -4.7% |
| YTD | +22.7% | +776.2% | -753.4% | +13.0% |
| 1Y | +32.0% | +987.9% | -955.9% | +18.9% |
| All | +32.0% | +945.0% | -913.0% | +18.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling